APN01 is an ACE2 mimic, and in a treated patient it forms a soluble ACE2/APN01 complex to which the virus binds as opposed to binding to the ACE2 on the cell walls, and therefore does not infect the cells. This is the first drug that targets SARS-COV2 directly.
APN01 also reduces the inflammatory response that results in lung injury.
Will be trialed on patients in Austria, Denmark and Germany, with the Austrian government paying for a lot of the trial’s costs.
Good. I hope it works and exceeds expectations.
Snake oil. 200 people isn’t a trial, even for phase 1. Don’t get people’s hopes up!
.
.
.
.
.
.
JK, hope it works. We need a good turn.
200 patients is about right for a Phase II study if they are split into control and treatment arms of 100 each. 
This is a true double blind study. Some of the other studies are not double blinded but simple comparison against standard of care. The reason those studies were designed that way is that they thought volunteers might be unwilling to take a 50/50 shot they’d only get placebo.
If this works, I wonder if they’ll even have to do a Ph III study. Ph III usually compares your drug against what else is out there that’s approved.
There is nothing else out there.
